NephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study (Preprint) DOI
Matthieu-P. Schapranow, Mozhgan Bayat, Aadil Rasheed

и другие.

Опубликована: Май 10, 2023

BACKGROUND Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis complex data a wide range daily-life cases. We aim to explore benefits applying AI specific case transplant nephrology: risk prediction severe posttransplant events. For first time, we combine multinational real-world data, which require legal technical protection measures. OBJECTIVE The German-Canadian NephroCAGE consortium aims develop evaluate processes, tools, methods (1) more than 8000 cases over past decades from leading centers Germany Canada, (2) implement measures protect sensitive (3) as foundation developing high-quality prognostic models. METHODS To addressing second objectives, decentralized federated learning infrastructure upon private blockchain. Our enables switch paradigms: instead pooling into central database analysis, it transfer clinical models (CPMs) sites local analyses. Thus, reside protected their original while comparable small are exchanged instead. our third objective, will compare performance selected algorithms, example, random forest extreme gradient boosting, CPMs predict short- long-term risks, graft failure or mortality. be trained on donor recipient retrospective cohorts kidney patients. RESULTS have received initial funding February 2021. All partners applied ethics approval 2022. process exploration variable extraction has started at all In total, 8120 patient records been retrieved August 2023. development validation is ongoing CONCLUSIONS nephrology such basis training privacy-preserving way, system investigate population specifics, understand heterogeneity, treatment specificities, individual impact outcomes. CLINICALTRIAL

INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48892

Язык: Английский

CAR-NK/CAR-T Cells: Emerging Immunotherapy of Cancer DOI
Noha Mousaad Elemam, R.A. Youness,

Abdelhamid M. Abdelhamid

и другие.

Interdisciplinary cancer research, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

0
BRD4 inhibitor reduces exhaustion and blocks terminal differentiation in CAR-T cells by modulating BATF and EGR1 DOI Creative Commons

Songnan Sui,

Mengjun Zhong, Shuxin Zhong

и другие.

Biomarker Research, Год журнала: 2024, Номер 12(1)

Опубликована: Окт. 15, 2024

Exhaustion is a key factor that influences the efficacy of chimeric antigen receptor T (CAR-T) cells. Our previous study demonstrated bromodomain protein 4 (BRD4) inhibitor can revise phenotype and function exhausted cells from leukemia patients. This aims to elucidate mechanism by which BRD4 reduces CAR-T cell exhaustion using single-cell RNA sequencing (scRNA-Seq).

Язык: Английский

Процитировано

0
Natural killer cell-based therapies in neuroblastoma DOI

Abtin Ghasempour,

Rashin Mohseni, Pouya Mahdavi Sharif

и другие.

Cellular Immunology, Год журнала: 2024, Номер 407, С. 104898 - 104898

Опубликована: Ноя. 28, 2024

Язык: Английский

Процитировано

0
Next frontier in cancer treatment: an iPSC supported CAR-T cell therapies DOI Open Access

Tayyaba Sona

Asia-Pacific Journal of Oncology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 27, 2024

The spread of cancer and huge number related deaths has made it imperative for scientist to search new diagnostic, prognostic treatment tools its effective management. Chimeric Antigen Receptor (CAR) T-cell (CAR-T) therapy been brought into limelight as novel strategy cancer. In this review we briefly introduced the CAR-T highlighting successful application various cancers along with possibility integrating induced pluripotent stem cell (iPSC) technology overcome intrinsic limitation. mechanism is based on isolation white blood cells through leukapheresis from patients’ or healthy donors followed by T-cells (a type immune cells). isolated are engineered using a viral vector other methods incorporate CAR gene expanded in lab. This modification enables T distinguish attack antigens surfaces cells. However, approach not without inherent limitations. notable limitation exhaustible availability within donor patient system, which can restrict feasibility effectiveness therapeutic intervention. A potential solution may lie synergizing technology. iPSC lies ability provide an endless supply resources. substantial amount research revealed production human Therefore, such combinatorial utilizing mounting immunological against continues iPSCs prove revolutionary designing pragmatic treatment.

Язык: Английский

Процитировано

0
NephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study (Preprint) DOI
Matthieu-P. Schapranow, Mozhgan Bayat, Aadil Rasheed

и другие.

Опубликована: Май 10, 2023

BACKGROUND Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis complex data a wide range daily-life cases. We aim to explore benefits applying AI specific case transplant nephrology: risk prediction severe posttransplant events. For first time, we combine multinational real-world data, which require legal technical protection measures. OBJECTIVE The German-Canadian NephroCAGE consortium aims develop evaluate processes, tools, methods (1) more than 8000 cases over past decades from leading centers Germany Canada, (2) implement measures protect sensitive (3) as foundation developing high-quality prognostic models. METHODS To addressing second objectives, decentralized federated learning infrastructure upon private blockchain. Our enables switch paradigms: instead pooling into central database analysis, it transfer clinical models (CPMs) sites local analyses. Thus, reside protected their original while comparable small are exchanged instead. our third objective, will compare performance selected algorithms, example, random forest extreme gradient boosting, CPMs predict short- long-term risks, graft failure or mortality. be trained on donor recipient retrospective cohorts kidney patients. RESULTS have received initial funding February 2021. All partners applied ethics approval 2022. process exploration variable extraction has started at all In total, 8120 patient records been retrieved August 2023. development validation is ongoing CONCLUSIONS nephrology such basis training privacy-preserving way, system investigate population specifics, understand heterogeneity, treatment specificities, individual impact outcomes. CLINICALTRIAL

INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48892

Язык: Английский

Процитировано

0